VIP Call Girls Sector 67 Gurgaon Just Call Me 9711199012
Translatum Medicus, Inc.
1. TMi de-risks & accelerates drug development for
“dry” Age Related Macular Degeneration
2. TMi de-risks & accelerates drug development for dry AMD
Shelley Boyd, MD, FRCSC
Clinician-Scientist, Ophthalmologist, specializing in diseases of the Retina
formerly Global Head, Ocular Angiogenesis Research Program, Novartis, Switzerland
Founder & Chief Scientific Officer, TMi
3. Age Related Macular Degeneration
Dry AMD
85%
Geographic atrophy (GA)
= loss of the photoreceptors & retinal
pigment epithelium (RPE)
the leading cause of
blindness in developed
world
Multi-billion $ market
No approved therapies
4. The Challenge
1) complex disease of innate immunity
2) no animal models develop dry AMD
3) clinical trial design is complex
4) sustained release will be required
Mariam Karmal, AAO EyeNet, 2011
15. Macrophages RPE
… with excess M1 activity
M1 macrophage mRNA
mRNAfoldchange
Time (days/weeks/months)BL
16. Macrophages RPE
… with shift in M1/M2 polarization
M1 macrophage mRNA
mRNAfoldchange
Time (days/weeks/months)BL
17. 2. Lead compound TMi-018
1st in class transcriptional regulator
proximal
Basal conditions
mRNA
distal proximal
Inflammatory conditions
mRNA
18. B. Lead compound TMi-018
1st in class transcriptional regulator reduces M1-related gene expression
X
proximal
Basal conditions
mRNA
distal proximal
Inflammatory conditions
mRNA
27. TMi-018 – known to be clinically safe
• demonstrated to be safe in Phase II clinical trial
• for non-ophthalmic autoimmune disease
• 400+ patients
• known MoA & confirmed druggable target
• demonstrated scalability for GMP production
28. TMi-018 - LMW compound suitable for sustained release
time
dose
29. • successfully prosecuted US Patent Office
• on accelerated Patent Prosecution Highway internationally
Cooley LLP, Morgan Lewis LLP
TMi-018 - patent protected
30. TMi de-risks drug development
B. Lead compound – TMi-018
• 1st in-class regulator of M1 macrophages
• is dose-dependently efficacious reducing onset & expansion of GA
• is systemically safe
• is scalable
• is patent-protected
A. Animal model uniquely mimics disease
• aligns with acceptable clinical trial endpoints
• and supports role of macrophages
31. • Transition to early phase clinical trial
• ocular toxicity
• IND approval from US FDA
TMi is poised to accelerate:
32. TMi has raised seed funds
• closed seed round of investment, effective October 31st, 2015
• in discussions for next rounds
33. President & CSO: Shelley Boyd, formerly Head Ocular Angiogenesis Research Program, Novartis
Chief Business Officer: Wayne Schnarr, formerly VP Oncolytics Biotech, Equicom
Strategic Advisory Committee:
Mike Grey, Pappas Ventures; formerly CEO Lumena, SGX, VP Corporate Development, Glaxo
Scientific & Medical Advisory Committee:
David Boyer, KOL, Retina Associates
Julia Levy, formerly CEO &CSO, QLT
Barrett Katz, Director, Clinical Trials, Albert Einstein, NY; formerly CMO Fovea, CEO Danube
TMi’s team